{
    "clinical_study": {
        "@rank": "104160", 
        "acronym": "CPCT-01", 
        "arm_group": {
            "arm_group_label": "Irinotecan", 
            "description": "Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the \"index lesion\" (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.\nSide studies include:\npharmacogenetics\npharmacokinetics of SN-38\ncarboxylesterase activity in the index lesion\nmidazolam clearance test (only in Rotterdam patients)"
        }, 
        "biospec_descr": {
            "textblock": "Histological biopsies Blood samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether it is possible to predict response to\n      chemotherapy in patients with metastatic cancer who are treated with irinotecan by\n      determining the mutational profile of the tumor."
        }, 
        "brief_title": "Biomarker Development for Response Prediction by DNA Mutational Analysis", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasm Metastasis", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with a metastatic solid tumor who have failed at least one line of\n             palliative chemotherapy and are irinotecan na\u00efve.\n\n          2. Patients who are, as per local protocol, eligible for palliative treatment with\n             (standard of care) irinotecan.\n\n          3. Measurable metastatic lesion(s), according to RECIST 1.1 criteria.\n\n          4. Radiological measurable metastatic lesion(s) of which a histological biopsy can\n             safely be obtained:\n\n               1. Patients with safely accessible metastases.\n\n               2. Patients not known with bleeding disorders (such as hemophilia) or bleeding\n                  complications from biopsies, dental procedures or surgeries.\n\n               3. Patients not using any anti-coagulant medication at the time of biopsy: all\n                  aspirin derivatives, NSAID's, coumarines, platelet function inhibitors, heparins\n                  (including LMWHs) and oral factor Xa inhibitors are not allowed, unless\n                  medication can either be safely stopped or counteracted.\n\n               4. Adequate coagulation status on the day of biopsy as measured by:\n\n                    -  PTT < 1.5 x ULN\n\n                    -  APTT < 1.5 x ULN\n\n                    -  Platelet count 100 x 10*9 / L or higher\n\n                    -  PT-INR < 1.6\n\n                    -  HB > 6\n\n               5. Biopsies should be performed at least four weeks after last bevacizumab\n                  administration.\n\n          5. Patients age 18 years or up, willing and able to comply with the protocol as judged\n             by the investigator with a signed informed consent.\n\n        Exclusion Criteria:\n\n        Patients not meeting all of the above inclusion criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with a metastatic solid tumor who are eligible for (standard of care) treatment\n        with irinotecan."
            }
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855061", 
            "org_study_id": "NL35198.041.11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Irinotecan", 
                "description": "Histological biopsy of the \"index lesion\" (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity.", 
                "intervention_name": "Biopsy", 
                "intervention_type": "Procedure", 
                "other_name": "Histological biopsy"
            }, 
            {
                "arm_group_label": "Irinotecan", 
                "description": "Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).", 
                "intervention_name": "Blood samples", 
                "intervention_type": "Procedure", 
                "other_name": "Blood sampling"
            }, 
            {
                "arm_group_label": "Irinotecan", 
                "description": "Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).", 
                "intervention_name": "Pharmacokinetics", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "PK", 
                    "Pharmacokinetic analysis", 
                    "Pharmacokinetic analyses"
                ]
            }, 
            {
                "arm_group_label": "Irinotecan", 
                "description": "Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.", 
                "intervention_name": "Midazolam clearance test", 
                "intervention_type": "Procedure", 
                "other_name": "MCT"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Midazolam", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Feasibility studies", 
            "Sequence analysis, DNA", 
            "Biological markers", 
            "Solid tumors", 
            "Neoplasm metastasis", 
            "Irinotecan", 
            "Pharmacokinetics SN-38", 
            "Carboxylesterase activity within metastasis"
        ], 
        "lastchanged_date": "February 23, 2014", 
        "location": [
            {
                "contact": {
                    "email": "n.steeghs@nki.nl", 
                    "last_name": "Neeltje Steeghs, MD/PhD", 
                    "phone": "+31205122570"
                }, 
                "contact_backup": {
                    "email": "m.roelvink@nki.nl", 
                    "last_name": "Marja Mergui-Roelvink, MD/PhD", 
                    "phone": "+31205122570"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "state": "North Holland", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital"
                }, 
                "investigator": {
                    "last_name": "Neeltje Steeghs, MD/PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "a.mathijssen@erasmusmc.nl", 
                    "last_name": "Ron Mathijssen, MD/PhD", 
                    "phone": "+3110703497"
                }, 
                "contact_backup": {
                    "email": "m.dejonge@erasmusmc.nl", 
                    "last_name": "Maja de Jonge, MD/PhD", 
                    "phone": "+31107041338"
                }, 
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "state": "South Holland", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Erasmsus Medical Center - Dani\u00ebl den Hoed clinic"
                }, 
                "investigator": {
                    "last_name": "Ron Mathijssen, MD/PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "m.p.j.lolkema@umcutrecht.nl", 
                    "last_name": "Martijn Lolkema, MD/PhD", 
                    "phone": "+31887556265"
                }, 
                "contact_backup": {
                    "email": "c.g.m.vanhooijdonk-3@umcutrecht.nl", 
                    "last_name": "Christa van Hooijdonk, MD/PharmD", 
                    "phone": "+31887556265"
                }, 
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "University Medical Center Utrecht"
                }, 
                "investigator": {
                    "last_name": "Miriam Koopman, MD/PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_groups": "1", 
        "official_title": "Feasibility Study of Biomarker Development for Response Prediction by Large Scale DNA Mutational Analysis of Metastatic Lesions", 
        "overall_contact": {
            "email": "m.p.j.k.lolkema@umcutrecht.nl", 
            "last_name": "Martijn Lolkema, MD/PhD", 
            "phone": "+31887556265"
        }, 
        "overall_contact_backup": {
            "email": "c.g.m.vanhooijdonk-3@umcutrecht.nl", 
            "last_name": "Christa Gadellaa-van Hooijdonk, MD, PharmD", 
            "phone": "+31887556265"
        }, 
        "overall_official": [
            {
                "affiliation": "UMC Utrecht", 
                "last_name": "Miriam Koopman, MD/PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam", 
                "last_name": "Neeltje Steeghs, MD/PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Erasmus Medical Center - Dani\u00ebl den Hoed clinic, Rotterdam", 
                "last_name": "Ron Mathijssen, MD/PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Exploration of the correlation between the mutational profile and the percentage change in volumetric measurement of the index lesion after the first two cycles of chemotherapy.", 
            "safety_issue": "No", 
            "time_frame": "Change in radiological volume of the index lesion after the first 2 cycles of irinotecan. Radiological response (according to RECIST 1.1) after the first 2 cycles of irinotecan (i.e. after 2 x 3 weeks = 6 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855061"
        }, 
        "responsible_party": {
            "investigator_affiliation": "UMC Utrecht", 
            "investigator_full_name": "Martijn P. Lolkema", 
            "investigator_title": "principal investigator, medical oncologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Exploration of the correlation between the mutational profile and radiological response according to RECIST-criteria after the first two cycles of chemotherapy.", 
                "safety_issue": "No", 
                "time_frame": "Analysis 6 weeks after initiation of treatment"
            }, 
            {
                "measure": "Exploration of the correlation between the mutational profile and progression free survival and overall survival.", 
                "safety_issue": "No", 
                "time_frame": "Overall survival approximately after 2 years of first cycle of irinotecan. Progression free survival approximately 3 months after first irinotecan"
            }, 
            {
                "measure": "Exploration of the correlation between the mutational profile of the index lesion and patient's germline DNA background variation.", 
                "safety_issue": "No", 
                "time_frame": "Analysis after progressive disease, on average after 3 months."
            }, 
            {
                "measure": "Differences in mutational profile of metastasis prior to and after exposure to treatment.", 
                "safety_issue": "No", 
                "time_frame": "Analysis after progressive disease and subsequent post-treatment biopsy, on average after 3 months of treatment"
            }, 
            {
                "measure": "Determine reliable and valid strategies for statistical analysis for biomarker discovery", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Correlate response to pharmacokinetics of SN-38", 
                "safety_issue": "No", 
                "time_frame": "After progressive disease and subsequent post-treatment biopsy, in general after 3 months of treatment"
            }, 
            {
                "measure": "Determine carboxylesterase activity in metastatic tumor material (pre- and posttreatment) and correlate intra-tumoral carboxylesterase activity to systemic SN-38 pharmacokinetics and to irinotecan response", 
                "safety_issue": "No", 
                "time_frame": "After progressive disease and subsequent post-treatment biopsy, in general after 3 months of treatment"
            }, 
            {
                "measure": "Determine clinical applicability of the midazolam phenotyping probe", 
                "safety_issue": "No", 
                "time_frame": "After first cycle of irinotecan, at three weeks"
            }, 
            {
                "measure": "Number and nature of all (serious) adverse events of study related procedures", 
                "safety_issue": "Yes", 
                "time_frame": "14 days after baseline biopsy and 14 days after post-treatment biopsy (approximately after 3 months of treatment)"
            }
        ], 
        "source": "UMC Utrecht", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Erasmus Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Netherlands Cancer Institute", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "UMC Utrecht", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}